# UCSF UC San Francisco Previously Published Works

# Title

ISSN

A Detailed Description of the Implementation of Inpatient Insulin Orders With a Commercial Electronic Health Record System

**Permalink** https://escholarship.org/uc/item/68555757

**Journal** Journal of Diabetes Science and Technology, 8(4)

1932-3107 **Authors** Neinstein, Aaron MacMaster, Heidemarie Windham Sullivan, Mary M

Sullivan, Mary M <u>et al.</u>

Publication Date 2014-07-01

# 2014-07-0

# DOI

10.1177/1932296814536290

Peer reviewed

# A Detailed Description of the Implementation of Inpatient Insulin Orders With a Commercial Electronic Health Record System

Journal of Diabetes Science and Technology 2014, Vol. 8(4) 641–651 © 2014 Diabetes Technology Society Reprints and permissions: sagepub.com/journalsPermissions.nav DOI: 10.1177/1932296814536290 dst.sagepub.com



Aaron Neinstein, MD<sup>1</sup>, Heidemarie Windham MacMaster, PharmD, CDE<sup>1</sup>, Mary M. Sullivan, DNP, ANP-BC, CDE, FAAN<sup>1</sup>, and Robert Rushakoff, MD<sup>1</sup>

#### Abstract

**Background:** In the setting of Meaningful Use laws and professional society guidelines, hospitals are rapidly implementing electronic glycemic management order sets. There are a number of best practices established in the literature for glycemic management protocols and programs. We believe that this is the first published account of the detailed steps to be taken to design, implement, and optimize glycemic management protocols in a commercial computerized provider order entry (CPOE) system.

**Process:** Prior to CPOE implementation, our hospital already had a mature glycemic management program. To transition to CPOE, we underwent the following 4 steps: (1) preparation and requirements gathering, (2) design and build, (3) implementation and dissemination, and (4) optimization. These steps required more than 2 years of coordinated work between physicians, nurses, pharmacists, and programmers. With the move to CPOE, our complex glycemic management order sets were successfully implemented without any significant interruptions in care. With feedback from users, we have continued to refine the order sets, and this remains an ongoing process.

**Conclusions:** Successful implementation of glycemic management protocols in CPOE is dependent on broad stakeholder input and buy-in. When using a commercial CPOE system, there may be limitations of the system, necessitating workarounds. There should be an upfront plan to apply resources for continuous process improvement and optimization after implementation.

#### Keywords

CPOE, diabetes mellitus, electronic health record (EHR), inpatient glycemic management, insulin

Implementing a physiologically based computerized provider order entry (CPOE) glycemic management program into the inpatient setting can be challenging for a health care organization. Beginning with a 2006 task force, the American Diabetes Association (ADA) and American College of Endocrinology (ACE) recommended that hospitals develop comprehensive inpatient glycemic management programs.<sup>1</sup> By 2008, 21% of hospitals had fully implemented protocols for noncritically ill patients, and 39% had done so for critically ill patients.<sup>2</sup> A few years later, in February 2009, the United States government enacted the Health Information Technology for Economic and Clinical Health (HITECH) Act, which through its Meaningful Use program laid out a series of financial incentives (and ultimately financial penalties) to encourage health care organizations to implement electronic health record (EHR) systems, including CPOE.<sup>3,4</sup>

Even before CPOE, establishing a comprehensive inpatient glycemic management system required years of planning;

significant education and coordination of medical, nursing, dietary, and pharmacy staff; and support from hospital administration and quality improvement departments. Transitioning this work into CPOE requires a similar effort as well as the coordination of the above disciplines with informaticists and EHR analysts. The implementation of such a major change into a health care organization requires incorporating the following processes: preparation and requirements gathering, design and build, validation and testing, education, implementation and dissemination, and optimization.

Several institutions have previously published their experiences toward creating a unified, comprehensive inpatient

<sup>1</sup>University of California, San Francisco, CA, USA

**Corresponding Author:** 

Aaron Neinstein, MD, University of California, San Francisco, 400 Parnassus Avenue, Suite A550, San Francisco, CA 94143-1222, USA. Email: aaron.neinstein@ucsf.edu

Adult hospital floors	Pediatric hospital floors	Obstetrics and gynecology hospital floors
SQ insulin for an eating patient	SQ insulin for an eating patient	SQ insulin for an eating patient
SQ insulin for NPO/ enteral/parenteral nutrition patient	IV insulin infusion	IV insulin infusion
DKA/hyperosmolar coma	Pediatric insulin pump	Insulin pump
ICU IV insulin infusion protocol	DKA protocol	
Medical-surgical IV insulin		
Adult insulin pump		

**Table 1.** Paper Insulin Order Forms Prior to CPOEImplementation.

CPOE, computerized provider order entry; DKA, diabetic ketoacidosis; ICU, intensive care unit; IV, intravenous; NPO, nil per os; SQ, subcutaneous.

glycemic management program, including experiences with both homegrown and commercial CPOE systems.<sup>5-10</sup> Although the benefits of CPOE for glycemic management have been discussed,<sup>6,7</sup> to date, there has not been a published comprehensive and detailed description of all the steps required for a successful transition to CPOE.

In this article, we describe our institution's experience and challenges over a 2-year period in transitioning our paperbased comprehensive inpatient glycemic management program to CPOE-based insulin order sets for glycemic management.

## Insulin Management Before CPOE

In the 1990s, at one of the hospitals at our medical center, we established the mandatory use of specific paper-based insulin order sets for all subcutaneous (SQ) and intravenous (IV) insulin use and for diabetic ketoacidosis (DKA). By 2004, all inpatient insulin orders for the entire medical center were required to be written using our preprinted insulin order forms. Nursing staff was educated on the use of these orders with mandatory, interactive Internet-based training. Pharmacists were oriented on the verification steps required to authorize the orders. Internet training for using these order sets was available for providers but was not mandatory. All medical and surgical interns had mandatory case-based training in small groups. While there were initially 4 order sets (for SQ insulin infusion, intensive care unit [ICU] IV insulin infusion, medical-surgical IV insulin infusion, and DKA), over time, this increased to 13 distinct paper order forms (Table 1).

Since 2003, we have had an inpatient glucose management committee comprising adult and pediatric endocrinologists, hospitalists, obstetricians, house staff, a diabetes nurse specialist, pharmacists, a risk management nurse, dietitians, and staff nurses from both pediatric and adult acute and critical care. This committee was involved in all aspects of inpatient glycemic management, developing the insulin order forms, monitoring glucometrics, and performing audits for insulin-related errors and adverse events. We performed a glucometric analysis in 2006 and found that after the implementation of paper insulin order sets, the mean glucose level for ICU patients on SQ insulin decreased from approximately 260 mg/dL to 155 mg/dL, with a <0.4% rate of glucose under 40 mg/dL. There were similar improvements in non-ICU patients.

Our practices on paper adhered to many best practices for inpatient glycemic management. Some examples include having distinct order sets for specific clinical scenarios (ie, indication-based order sets), a restricted hospital formulary, defaulted nursing instructions (eg, to hold nutritional insulin dosing when food is held), nursing education and in-services, matching the timing of fingerstick glucose checks to meal times and insulin delivery, and having a hospital inpatient diabetes committee.<sup>11</sup>

In 2010, our institution began the process of implementing a new EHR (EpicCare, Epic System, Verona, WI) with the goal of completing implementation in all inpatient and ambulatory areas by June 2012. We quickly discovered that attempting a literal translation of paper order forms into CPOE does not work. For example, with paper order forms, a provider can alter the preprinted orders by crossing something out or writing something in. This almost infinite degree of flexibility is not possible with CPOE, in which the order set must be designed to support all likely orders, and there must be some method for a provider to place more rare orders.

### Step 1: Preparation and Requirements Gathering

Fortunately, because we had already assembled an inpatient glucose management committee with broad representation, building our team did not occur from scratch. New to our team and leading our work were a clinical pharmacist and clinical informaticist trained in developing and customizing order sets for our EHR. He was joined by a clinical pharmacist and nurses trained in our EHR system who understood the ways in which the orders would translate into administration instructions. This work was overseen by a new hospital committee repurposed from managing the development of all paper order sets and now in charge of all CPOE order sets.

Our primary design objectives for glycemic management order sets for CPOE were to make them: (1) physiological (ie, basal-bolus insulin rather than sliding scale); (2) consistent with our formulary; (3) comprehensive in containing insulin orders, hypoglycemia protocol orders, prescribing guidelines, and clear administration instructions; and (4) contain safeguards to decrease potential errors at the time of order entry, verification, or administration. We first assessed the vendor-provided sample insulin order sets and found that they did not support our needs. We contacted several institutions using the same EHR and also found that they were either in the process of developing customized order sets or had built order sets that also did not meet our objectives.

		Sub-Section Defaulted and/or		Specific Order Defaulte
Order Set Section	Order Set Sub-Section	Multi-Select?	Specific Order	and/or Multi-Select?
Seneral orders			Discontinue all previous insulin orders.	Defaulted, Multi-Select
			Check blood glucose before meals, bedtime, and at 2am.	Defaulted, Multi-Select
			Give insulin before meals, bedtime, and at 2 am.	Defaulted, Multi-Select
	If patient becomes NPO for procedure or stops eating:	Defaulted, Multi-Select	HOLD nutritional dose of aspart	Defaulted, Multi-Select
			Continue Glargine if BG not <70 mg/dL in last 24 hours	Defaulted, Multi-Select
			Continue correctional doses as per orders	Defaulted, Multi-Select
			Notify MD Order if BG has been <70 mg/dL in last 24 hours	Defaulted, Multi-Select
Basal Insulin	Glargine (Recommended basal insulin)	Not Defaulted, Single Select	Glargineunits with breakfast	Not Defaulted, Multi-Select
			Glargine units with dinner	Not Defaulted, Multi-Select
			Glargine units at bedtime	Defaulted, Multi-Select
	NPH BID	Not Defaulted, Single Select	NPH units with breakfast	Defaulted, Multi-Select
			NPH units with dinner	Defaulted, Multi-Select
	NPH Bedtime	Not Defaulted, Single Select	NPH units at bedtime	Defaulted, Multi-Select
	Insulin 70/30 Novalog-mix (For Endocrinology only)	Not Defaulted, Single Select	70/30 units with breakfast	Defaulted, Multi-Select
			70/30 units with dinner	Defaulted, Multi-Select
Aspart Nutritional + Correctional Insulin	Sensitive (BMI less than 25 and/or <50 units of insulin per day)	Not Defaulted, Single Select	Aspart units with breakfast and Sliding Scale	Defaulted, Multi-Select
			Aspart units with Lunch and Sliding Scale	Defaulted, Multi-Select
			Aspart units with Dinner and Sliding Scale	Defaulted, Multi-Select
			Aspart bedtime and 2am sliding scale	Defaulted, Multi-Select
	Average (BMI 25-30 and/or 50-90 units of insulin per day)	Not Defaulted, Single Select	Aspart units with breakfast and Sliding Scale	Defaulted, Multi-Select
			Aspart units with Lunch and Sliding Scale	Defaulted, Multi-Select
			Aspartunits with Dinner and Sliding Scale	Defaulted, Multi-Select
			Aspart bedtime and 2am sliding scale	Defaulted, Multi-Select
	Resistant (BMI >30 and/or >90 units of insulin per day)	Not Defaulted, Single Select	Aspart units with breakfast and Sliding Scale	Defaulted, Multi-Select
			Aspart units with Lunch and Sliding Scale	Defaulted, Multi-Select
			Aspart units with Dinner and Sliding Scale	Defaulted, Multi-Select
			Aspart bedtime and 2am sliding scale	Defaulted, Multi-Select
	Custom	Not Defaulted, Single Select	Aspart units with breakfast and Sliding Scale	Defaulted, Multi-Select
			Aspart units with Lunch and Sliding Scale	Defaulted, Multi-Select
			Aspart units with Dinner and Sliding Scale	Defaulted, Multi-Select
			Aspart bedtime and 2am sliding scale	Defaulted, Multi-Select
Hypoglycemia Protocol	Hypoglycemia Protocol	Defaulted, Single Select	dextrose injection prn	Defaulted, Multi-Select
			glucose chewable prn	Defaulted, Multi-Select
			give fruit juice prn	Defaulted, Multi-Select
			check fingerstick prn	Defaulted, Multi-Select

Figure 1. Spreadsheet translating paper orders into electronic orders. This spreadsheet shows our "work in progress" translation of paper order forms into a format that could be built into computerized provider order entry order sets.

### Step 2: Design and Build

Initially, 2 of us (R.R., M.M.S.) who had been involved in the development of all the paper order sets met with the informaticist (A.N.) tasked with aiding the transition from paper insulin order sets to CPOE. Through the course of 3 meetings and dozens of emails back and forth, the paper order sets were translated into spreadsheets to help visualize the hierarchy of orders and which orders were required or defaulted. An example is shown in Figure 1. This presented the opportunity to make key improvements from paper order sets, such as adding orders that matched the timing of insulin dosing with cycled enteral or parenteral nutrition or adding carbohydrate (CHO)–based SQ insulin administration options.

The initial design of the new CPOE order sets was based on these detailed spreadsheets, and over the subsequent 3 months, the layout of the various insulin order sets was established. Our goal was to standardize the layout and functions of the many different order sets.

We quickly encountered challenges. As with most institutions, our paper SQ insulin order set requested a dose for nutritional insulin and then a selection from a separate correctional dose table to help the nurse calculate the total premeal insulin dose that the patient should receive (Figure 2).

With our CPOE system, separate orders for nutritional and correctional insulin doses would display separately on the medication administration record [MAR], potentially far apart from each other on a nursing administration screen. We learned from other institutions that this could result in mathematical errors, duplicated injections, or omission of either the nutritional or correctional insulin dose. To avoid this, we decided to group together the nutritional and correctional insulin orders as 1 insulin order (Figure 3).

Thus, on all SQ insulin order sets, the first step for the prescribing provider would be to choose a rapid-acting insulin based on whether the patient would require a sensitive, average, resistant, or custom correctional dose. Once making that choice, the nutritional insulin dose could be entered into the administration instructions. This workflow also served as embedded decision support, forcing providers to actively order zero units if no nutritional insulin dose was to be given, as opposed to just using "sliding scale" insulin.

One item of note is that the design and functional possibilities may vary greatly between different commercial EHRs. For example, as described in a prior article,<sup>12</sup> the usability principle of "natural mapping," or laying out an electronic system to match a person's mental model, was impossible to adhere to in designing insulin order sets in our CPOE system. It was not possible to design our order sets to make use of a tabular format, something that would be selfobvious and familiar to users because this is the conventional way to display insulin plans and the way that was used in our prior paper order forms.

Another issue that we encountered was how to handle changes in insulin orders, for example, changes in a nutritional insulin dose or for a patient transitioning from IV to SQ insulin. On paper, we had mandated that the provider fill out a completely new order set for any change, reducing the risk for duplicate orders. However, with CPOE, having to

Patient Eating TIME	Breakfast	Lunch	Dinner	Bedtime
Aspart (NovoLog) Nutritional Dose	units	units	units	units
	units	units	units	units
NPH	units		units	units
Glargine (Lantus)	units		units	units
NovoLog Mix 70/30	units	units	units	
B. MEAL TIME CORRE	CTIONAL Insulin with As	SPART. Check box to cho	ose scale. Add or subtract fro	m nutritional dose of aspart.
Blood Glucose Range:	☐ Sensitive BMI less than 25 and/or <50 units per day	Average BMI 25-30 and/or 50-90 units per day	Resistant     BMI >30 and/or     >90 units per day	Custom
<70 mg/dL	Treat for Hypoglycemia per pro	tocol (see order #6). Once BG	≥100 mg/dL give Aspart with follow	ving change when patient eats:
Once BG ≥100mg/dL give:	2 units less	3 units less	4 units less	units less
70-100 mg/dL	1 unit less	2 units less	3 units less	units less
101-130 mg/dL	Give nutritional dose Asp	art as in #4A above		·
131-150 mg/dL	0 unit	+1 unit	+2 units	+ units
151-200 mg/dL	+1 unit	+2 units	+3 units	+ units
201-250 mg/dL	+2 units	+4 units	+6 units	+ units
	+3 units	+6 units	+9 units	+ units
251-300 mg/dL		0	+12 units	+ units
	+4 units	+8 units	+12 units	+ units
251-300 mg/dL 301-350 mg/dL 351-400 mg/dL	+4 units +5 units	+8 units +10 units	+12 units +15 units	+ units

Figure 2. Paper insulin order set.

delete and re-enter a completely new order set seemed inefficient, so our team decided that we would allow modifications to the initial insulin order set. To help with transitioning from IV to SQ insulin, we embedded an SQ insulin dose in the IV infusion order sets.


Although the insulin sections of every order set were developed to specifically match the clinical state of the patient (eg, eating or nil per os [NPO]), all other sections of the order sets were standardized (Figure 4). A nursing orders section included the timing and restrictions for glucose monitoring for a predefined time standard (eg, premeal, bedtime, and 2 AM for patients eating; every 4 hours for a patient NPO or on enteral or parenteral nutrition) and included provider notification orders. A hypoglycemia orders section, required for all insulin order sets, also had defaulted orders for a hypoglycemia protocol.

As shown in Table 2, we built multiple insulin order sets. Other institutions have chosen to put insulin orders within the main admission order set to avoid workflow barriers,<sup>5</sup> but we chose to make our order sets separate from our admission order set to facilitate indication-based ordering. Within several of the order sets, we included the option to prescribe either fixed or CHO-based nutritional insulin doses. To avoid hypoglycemia in patients with poor appetites, a "postmeal" order set allowed nurses to adjust nutritional doses based on the amount of the meal that the patient ate, administering the dose immediately after the meal. To prevent insulin dose stacking and iatrogenic hypoglycemia in patients on enteral or parenteral nutrition, we coordinated with nutritional services and surgeons to standardize nutrition cycle times and insulin dosing. Twelve-hour nutrition cycles would all run from 1800 to 0600 hours, 14-hour cycles from 1800 to 0800 hours, and 16-hour cycles from 1800 to 1000 hours. These times are built directly into those order sets to eliminate possible errors. To prevent calculation errors when adding nutritional and correctional insulin doses, we created an insulin dose calculator to help nurses determine the proper rapid-acting insulin dose (Figure 5).

To assist providers in reviewing and adjusting insulin regimens, we built a review flowsheet (Figure 6) to allow providers to quickly view the last 24 hours of glycemic control information. This comprehensive flowsheet includes point of care glucose values, insulin doses administered, IV medications administered containing dextrose, the percentage of the meal consumed, enteral feeding type and administration rates, and any oral hypoglycemic agents administered. We hoped that this tool would help encourage providers to perform more frequent assessments and adjustments of insulin regimens.

#### Step 3: Implementation and Dissemination

Prior to our institution's inpatient EHR go-live in June 2012, all health care providers had to attend training courses specific



**Figure 3.** (A) Combined nutritional and correctional insulin order in computerized provider order entry (collapsed for initial order selection). (B) Administration instructions after selecting a combined nutritional and correctional insulin order in A (average scale). (C) Administration instructions after selecting a combined nutritional and correctional insulin order in A: bedtime and 2 AM dosing (average scale).

to their discipline. An optional computerized module was created to teach prescribers how to order insulin using the various order sets. Pharmacists were required to complete training, which included verification of the insulin orders as well as how to capture omissions or prescribing errors. Nurses were required to attend the Bar Code Medication Administration Simulation Laboratory, which had simulated cases on insulin administration. We created a guide sheet for nurses and providers to help them use the order sets appropriately.

### Step 4: Optimization

To optimize our CPOE glycemic management build, the Diabetes and Insulin Management Committee monitored the change requests that were submitted to the EHR build team. The Diabetes and Insulin Management Committee problemsolved solutions to enhance the order sets and provided additional on-site training to the providers.

One example of a change request was in response to our removal of individual insulin orders from the available medication list. We had done this to ensure that providers only used our insulin order sets, in contrast to what has been done in some other institutions where the use of these order sets was optional.<sup>13</sup> From experience, we did not want to allow for "rogue" insulin orders that could lead to misinterpretation, errors, duplicates, and orders placed without hypoglycemia protocol orders and other linked orders. So, for example, if a provider typed in "lispro" in the medication order field, he or she would not find anything. This decision caused a challenge in a patient admitted with elevated glucose levels due to a faulty insulin pump. The provider was unable to decide whether to commit to the insulin pump order set or the SQ insulin order set, causing a delay in care. This might have been ameliorated had the provider been able to place a 1-time insulin order. So, we created a workflow whereby there is an "order set" allowing a 1-time insulin order.

Nevertheless, a remaining problem is that we have a large number of duplicate orders in the system. In our CPOE system, there is no ability to automatically discontinue the prior insulin orders by placing a new insulin order set. Discontinuing the prior orders requires the providers to remember that they need to do so and to go to a separate screen to do this. Alternately, we could have turned on "duplicate order alerts," but the system is unable to distinguish between an undesired duplicate order such as 2 conflicting aspart insulin orders and a desired duplicate order such as glargine insulin and aspart insulin. Experience with medication alerting in CPOE has shown that this type of a lack of specificity of alerts would lead to them being unsuccessful.<sup>14</sup> Lee et al<sup>10</sup> reported that they were able to achieve this goal with their build in the Invision Siemens system by allowing for orders to be updated and changed rather than requiring new ones.

To combine our nutritional and correctional insulin doses into 1 order, we had to use a free-text administration instruction for these doses rather than the discrete dose field in the CPOE system. We used a minimum-maximum range in the discrete dose field. This unintentionally caused a large number of "high-dose" alerts from our First Data Bank alerting

Vursing - glucose	monitoring
Glucose, non-fas	ting
	STAT, PRN starting Today at 1603 Until Specified
	Container details: Gold top or Light Green top (Gray or Dark Green top acceptable)
POCT glucose. (	Check blood glucose and give insulin before meals, bedtime, and 2 AM
	Routine, Before Meals, At Bedtime and 0200 First occurrence Today at 1730 Until Specified
Votify Provider if	3G is <70 mg/dL or >400 mg/dL
	Routine, Continuous starting Today at 1604 Until Specified
Medications - Hypo	glycemia Protocol
- Hypoglycemia Pr	otocol
	otocol activate below Hypoglycemia Protocol. These orders remain active for duration of SQ insulin administration. Give one of the following fast-acting
For BG <70 mg/dL, a carbohydrate per pa	activate below Hypoglycemia Protocol. These orders remain active for duration of SQ insulin administration. Give one of the following fast-acting tient preference:
For BG <70 mg/dL, a carbohydrate per pa • Hypoglycemia Pr	activate below Hypoglycemia Protocol. These orders remain active for duration of SQ insulin administration. Give one of the following fast-acting tient preference: otocol
For BG <70 mg/dL, a carbohydrate per pa	activate below Hypoglycemia Protocol. These orders remain active for duration of SQ insulin administration. Give one of the following fast-acting tient preference: otocol injection 12.5 g
For BG <70 mg/dL, a carbohydrate per pa © Hypoglycemia Pr	activate below Hypoglycemia Protocol. These orders remain active for duration of SQ insulin administration. Give one of the following fast-acting tient preference: otocol injection 12.5 g 25 mL = 12.5 g, Intravenous, Every 15 Min PRN, hypoglycemia , Starting Today at 1603
For BG <70 mg/dL, a carbohydrate per pa • Hypoglycemia Pr	activate below Hypoglycemia Protocol. These orders remain active for duration of SQ insulin administration. Give one of the following fast-acting tient preference: otocol injection 12.5 g 25 mL = 12.5 g, Intravenous, Every 15 Min PRN, hypoglycemia , Starting Today at 1603 Give if patient cannot take PO or give 6 oz. Fruit pice. For BG-70 mg/dL, give a fast acting carbohydrate per patient preference or Dextrose IV per order if patient cannot take PO. Every 15 minute:
For BG <70 mg/dL, a carbohydrate per pa I Hypoglycemia Pr I dextrose 50%	activate below Hypoglycemia Protocol. These orders remain active for duration of SQ insulin administration. Give one of the following fast-acting titent preference: otocol injection 12.5 g 25 mL = 12.5 g, Intravenous, Every 15 Min PRN, hypoglycemia , Starting Today at 1603 Give if patient cannot take PO or give 6 oz. Fruit Juice. For BG<70 mg/dL, give a fast acting carbohydrate per patient preference or Dextrose IV per order if patient cannot take PO. Every 15 minuter Recheck blood glucose per POCT orders and repeat treatment until BC is >/= 100 mg/dL.
For BG <70 mg/dL, a carbohydrate per pa • Hypoglycemia Pr	activate below Hypoglycemia Protocol. These orders remain active for duration of SQ insulin administration. Give one of the following fast-acting tient preference: olocol injection 12.5 g 25 mL = 12.5 g, Intravenous, Every 15 Min PRN, hypoglycemia . Starting Today at 1603 Give if potient cannot take PO or give 6 oz. Fruit juice. For BG-r0 mg/dL, give a fast acting carbohydrate per patient preference or Dextrose IV per order if patient cannot take PO. Every 15 minute: Recheck blood glucose per POCT orders and repeat treatment until BG is >/= 100 mg/dL. able tablet 20 g
For BG <70 mg/dL, a carbohydrate per pa	activate below Hypoglycemia Protocol. These orders remain active for duration of SQ insulin administration. Give one of the following fast-acting titent preference: otocol injection 12.5 g 25 mL = 12.5 g, Intravenous, Every 15 Min PRN, hypoglycemia , Starting Today at 1603 Give if patient cannot take PO or give 6 oz. Frut juice. For BG-70 mg/dL, give a fast acting carbohydrate per patient preference or Dextrose IV per order if patient cannot take PO. Every 15 minute: Recheck biolog glucose per POCT orders and repeat treatment until BG is >/= 100 mg/dL. able tablet 20 g 20 g, Oral, Every 15 Min PRN, hypoglycemia, Starting Today at 1603
For BG <70 mg/dL, a carbohydrate per pa	activate below Hypoglycemia Protocol. These orders remain active for duration of SQ insulin administration. Give one of the following fast-acting tient preference: olocol injection 12.5 g 25 mL = 12.5 g, Intravenous, Every 15 Min PRN, hypoglycemia . Starting Today at 1603 Give if potient cannot take PO or give 6 oz. Fruit juice. For BG-r0 mg/dL, give a fast acting carbohydrate per patient preference or Dextrose IV per order if patient cannot take PO. Every 15 minute: Recheck blood glucose per POCT orders and repeat treatment until BG is >/= 100 mg/dL. able tablet 20 g
For BG <70 mg/dL, a carbohydrate per pa	activate below Hypoglycemia Protocol. These orders remain active for duration of SQ insulin administration. Give one of the following fast-acting titent preference: otocol injection 12.5 g 25 mL = 12.5 g, Intravenous, Every 15 Min PRN, hypoglycemia , Starting Today at 1603 Give if patient cannot take PO ar give 6 oz. Fruit juice. For BG-70 mg/dL, give a fast acting carbohydrate per patient preference or Dextrose IV per order if patient cannot take PO. Every 15 minute: Recheck blood glucose per POCT orders and repeat treatment until BG is >/= 100 mg/dL. able tablet 20 g 20 g, Oral, Every 15 Min PRN, hypoglycemia, Starting Today at 1603 For BG-70 mg/dL, give a fast acting carbohydrate per patient preference if patient is taking PO. Every 15 minutes: Recheck blood glucose per POCT orders and repeat treatment until BG is >/= 100 mg/dL. May substitute with 605 cm/l juice and document in appropriate nursing flowsheet.
For BG <70 mg/dL, a carbohydrate per pa r Hypoglycemia Pr r dextrose 50%	activate below Hypoglycemia Protocol. These orders remain active for duration of SQ insulin administration. Give one of the following fast-acting titent preference: otocol injection 12.5 g 25 mL = 12.5 g, Intravenous, Every 15 Min PRN, hypoglycemia , Starting Today at 1603 Give if patient cannot take PO ar give 6 oz. Fruit juice. For BG-70 mg/dL, give a fast acting carbohydrate per patient preference or Dextrose IV per order if patient cannot take PO. Every 15 minute: Recheck blood glucose per POCT orders and repeat treatment until BG is >/= 100 mg/dL. able tablet 20 g 20 g, Oral, Every 15 Min PRN, hypoglycemia, Starting Today at 1603 For BG-70 mg/dL, give a fast acting carbohydrate per patient preference if patient is taking PO. Every 15 minutes: Recheck blood glucose per POCT orders and repeat treatment until BG is >/= 100 mg/dL. May substitute with 605 cm/l juice and document in appropriate nursing flowsheet.

Figure 4. Defaulted nursing and hypoglycemia protocol orders. Every glycemic management order set was built with preselected orders to standardize nursing care and hypoglycemia protocol orders.

Hospital.	
Order set	Insulin-related contents of order set
Adult SQ insulin for	Basal and premeal (fixed dosing)
an eating patient (premeal dosing)	Basal and premeal (CHO-based dosing)
Adult SQ insulin for	Basal and postmeal (based on CHO

Table 2.	CPOE Glycemic Management Order Sets for Adult
Hospital.	

Adult SQ insulin for an eating patient (premeal dosing)	Basal and premeal (fixed dosing) Basal and premeal (CHO-based dosing)
Adult SQ insulin for an eating patient	Basal and postmeal (based on CHO consumed)
(postmeal dosing)	Basal and postmeal (based on total amount consumed)
Adult SQ insulin: NPO or parenteral	Basal and Q4h nutrition and correction
nutrition	Basal, nutrition dose timed to cycle parenteral nutrition, and Q4h correction
Adult SQ insulin: enteral nutrition	Basal and Q4h nutrition and correction
	Basal, nutrition dose timed to cycle feedings, Q4h correction
Adult insulin pump	Basal rates, CHO ratios, correction sensitivity, and specific orders on both patient and nursing responsibilities
IV insulin protocol for ICU	IV insulin algorithm, specific initial rate for DKA or cardiac surgery
IV insulin protocol for medical-surgical units	IV insulin algorithm, specific initial rate for DKA or cardiac surgery
DKA protocol	IV insulin orders and follow-up laboratory tests

These are our current glycemic management order sets for the adult hospital. Other order sets (not shown here) exist for pediatric and obstetric patients. CHO, carbohydrate; CPOE, computerized provider order entry; DKA, diabetic ketoacidosis; ICU, intensive care unit; IV, intravenous; NPO, nil per os; Q4h, every 4 hours; SQ, subcutaneous.

system. We decided to turn off the high-dose insulin alerts to reconcile this problem, realizing that the alerts in this case were all false-positives.

We have faced additional challenges during optimization. It has been difficult to maintain the necessary resources to continually update our original work after the initial implementation effort. Also, changes in practice cannot be accomplished just by changing order sets, and we have been challenged to get all providers to complete the training and educational modules.

## Discussion

Several considerations are critical while developing CPOE glycemic management order sets, a process we have laid out in Figure 7. The implementation team should give equal consideration to all elements of the workflow, such as initial provider order placement, pharmacy verification, and nurse insulin administration. Changing the way that an order looks to a provider will have important downstream consequences on how the order looks to a nurse or pharmacist (Figure 8). Having all stakeholders present to ensure that the build meets their needs is important. Providers, nurses, and pharmacists should receive education on how to use the order sets. It is important to have processes in place for continuous quality improvement so that the order sets can be improved and updated based on user experience and feedback. As shown in Figure 9, some of our order sets are rarely used, such as the order set that accounts for patients who might not finish their food, allowing rapid-acting insulin to be given after the meal rather than before the meal. One limitation of this article is that we have not included data comparing hospital

Provide State	in RN Verify					
Time taken: 1411	4/14/2014					
Values By			-			
POCT Blood Glucos	se Result					
Blood Glucose	210	7				
(mg/dL)- manual entry						
Aspart/Lispro/Regulation	lar- Non-Carbohydra	te Based Patient				
Nutritional Dose (unit)	3					
Correctional Dose (unit)	<b>D</b> 6					
Total Dose (unit)	9					
- Aspart/Lispro- Carb	ohydrate Based Pat	ient				
Carbohydrate Intake (gram)	D	]				
1 unit of Insulin per "entered value" grams of Carbohydrate	0					
Nutritional Dose (unit)	а.					
Correctional Dose (unit)	۵ <u> </u>		5.			
Total Dose (unit)		1	-2			
	Insulin Type					
Basal Dose (unit)		1				
		<u> </u>				
Basal Dose (unit)	D I	3				
		2				
Basal Dose (unit)	-	1				
			1			
	-	1				
Basal Dose (unit)						
💣 Insulin RN Verify						click to op
A New Deeding						Go to Doc Flowshe
New Reading					04/42/44	
· New Reading	04/13/14	04/13/14	04/13/14 1203	04/13/14	04/13/14 2052	04/14/14
New Reading     POCT Blood Glucose I	0113	04/13/14 0820	04/13/14 1203	04/13/14 1743	2052	04/14/14 1411
POCT Blood Glucose I Blood Glucose	0113					
POCT Blood Glucose I Blood Glucose (mg/dL)- manual entry	0113 Result 229	0820	1203	1743	2052	1411
POCT Blood Glucose I Blood Glucose	0113 Result 229	0820	1203	1743	2052	1411
POCT Blood Glucose I Blood Glucose (mg/dL)- manual entry Aspart/Lispro/Regular. Nutritional Dose (unit) Correctional Dose	0113 Result 229 - Non-Carbohydrate B	0820 198 ased Patient	1203 214	1743 165	2052 196	1411 210
POCT Blood Glucose I Blood Glucose (mg/dL)- manual entry Aspart/Lispro/Regular. Nutritional Dose (unit) Correctional Dose (unit)	0113 Result 229 - Non-Carbohydrate B 0 2	0820 198 ased Patient 2 2	1203 214 3 6	1743 165 3 3	2052 196 0 0	1411 210 3 6
POCT Blood Glucose I Blood Glucose (mg/dL)- manual entry Aspart/Lispro/Regular. Nutritional Dose (unit) Correctional Dose	0113 Result 229 - Non-Carbohydrate B 0 2 2 (calculated)	0820 198 ased Patient 2	1203 214 3	1743 165 3	2052 196 0	1411 210 3
POCT Blood Glucose I Blood Glucose (mg/dL)- manual entry Aspart/Lispro/Regular. Nutritional Dose (unit) Correctional Dose (unit) Total Dose (unit) Aspart/Lispro- Carbohy Carbohydrate Intake	0113 Result 229 - Non-Carbohydrate B 0 2 2 (calculated)	0820 198 ased Patient 2 2	1203 214 3 6	1743 165 3 3	2052 196 0 0	1411 210 3 6
POCT Blood Glucose I Blood Glucose (mg/dL)- manual entry Aspart/Lispro/Regular. Nutritional Dose (unit) Correctional Dose (unit) Total Dose (unit) Aspart/Lispro- Carbohy Carbohydrate Intake (gram) 1 unit of Insulin	0113 Result 229 - Non-Carbohydrate B 0 2 2 (calculated)	0820 198 ased Patient 2 2	1203 214 3 6	1743 165 3 3	2052 196 0 0	1411 210 3 6
POCT Blood Glucose I Blood Glucose (mg/dL)- manual entry Aspart/Lispro/Regular. Nutritional Dose (unit) Correctional Dose (unit) Total Dose (unit) Aspart/Lispro- Carbohy Carbohydrate Intake (gram) 1 unit of Insulin per "entered value" grams of Carbohydrate	0113 Result 229 - Non-Carbohydrate B 0 2 2 (calculated)	0820 198 ased Patient 2 2	1203 214 3 6	1743 165 3 3	2052 196 0 0	1411 210 3 6
POCT Blood Glucose I Blood Glucose (mg/dL)- manual entry Aspart/Lispro/Regular. Nutritional Dose (unit) Correctional Dose (unit) Total Dose (unit) Aspart/Lispro- Carbohy Carbohydrate Intake (gram) 1 unit of Insulin per "entered value" grams of Carbohydrate Nutritional Dose (unit) Correctional Dose	0113 Result 229 - Non-Carbohydrate B 0 2 2 (calculated)	0820 198 ased Patient 2 2	1203 214 3 6	1743 165 3 3	2052 196 0 0	1411 210 3 6
POCT Blood Glucose I Blood Glucose (mg/dL)- manual entry Aspart/Lispro/Regular. Nutritional Dose (unit) Correctional Dose (unit) Total Dose (unit) Aspart/Lispro-Carbohy Carbohydrate Intake (gram) 1 unit of Insulin per "entered value" grams of Carbohydrate Nutritional Dose (unit) Correctional Dose (unit) Correctional Dose (unit) Total Dose (unit)	0113 Result 229 - Non-Carbohydrate B 0 2 2 (calculated) ydrate Based Patient	0820 198 ased Patient 2 2	1203 214 3 6	1743 165 3 3	2052 196 0 0	1411 210 3 6
POCT Blood Glucose I Blood Glucose (mg/dL)- manual entry Aspart/Lispro/Regular. Nutritional Dose (unit) Correctional Dose (unit) Total Dose (unit) Aspart/Lispro- Carbohy Carbohydrate Intake (gram) 1 unit of Insulin per "entered value" grams of Carbohydrate Nutritional Dose (unit) Correctional Dose (unit) Correctional Dose (unit) Glargine (Lantus) - Ins	0113 Result 229 - Non-Carbohydrate B 0 2 2 (calculated) ydrate Based Patient	0820 198 ased Patient 2 2	1203 214 3 6	1743 165 3 3	2052 196 0 0	1411 210 3 6
POCT Blood Glucose I Blood Glucose (mg/dL)- manual entry Aspart/LisprofRegular. Nutritional Dose (unit) Correctional Dose (unit) Total Dose (unit) Aspart/Lispro- Carbohy Carbohydrate Intake (gram) 1 unit of Insulin per "entered value" grams of Carbohydrate Nutritional Dose (unit) Correctional Dose (unit) Correctional Dose (unit) Cortal Dose (unit) Total Dose (unit) Glargine (Lantus) - Ins Basal Dose (unit) NPH - Insulin Type	0113 Result 229 - Non-Carbohydrate B 0 2 2 (calculated) ydrate Based Patient	0820 198 ased Patient 2 2	1203 214 3 6	1743 165 3 3	2052 196 0 0 0 (calculated)	1411 210 3 6
POCT Blood Glucose I Blood Glucose (mg/dL)- manual entry Aspart/Lispro/Regular. Nutritional Dose (unit) Correctional Dose (unit) Total Dose (unit) Aspart/Lispro-Carbohy Carbohydrate Intake (gram) 1 unit of Insulin per "entered value" grams of Carbohydrate Nutritional Dose (unit) Correctional Dose (unit) Total Dose (unit) Glargine (Lantus) - Ins Basal Dose (unit) NPH - Insulin Type Basal Dose (unit)	0113 Result 229 - Non-Carbohydrate B 0 2 2 (calculated) ydrate Based Patient	0820 198 ased Patient 2 2	1203 214 3 6	1743 165 3 3	2052 196 0 0 0 (calculated)	1411 210 3 6
POCT Blood Glucose I Blood Glucose (mg/dL)- manual entry Aspart/LisprofRegular. Nutritional Dose (unit) Correctional Dose (unit) Total Dose (unit) Aspart/Lispro- Carbohy Carbohydrate Intake (gram) 1 unit of Insulin per "entered value" grams of Carbohydrate Nutritional Dose (unit) Correctional Dose (unit) Correctional Dose (unit) Cortal Dose (unit) Total Dose (unit) Glargine (Lantus) - Ins Basal Dose (unit) NPH - Insulin Type	0113 Result 229 - Non-Carbohydrate B 0 2 2 (calculated) ydrate Based Patient	0820 198 ased Patient 2 2	1203 214 3 6	1743 165 3 3	2052 196 0 0 0 (calculated)	1411 210 3 6
POCT Blood Glucose I Blood Glucose (mg/dL)- manual entry Aspart/Lispro/Regular. Nutritional Dose (unit) Correctional Dose (unit) Total Dose (unit) Aspart/Lispro-Carbohy Carbohydrate Intake (gram) 1 unit of Insulin per "entered value" grams of Carbohydrate Nutritional Dose (unit) Correctional Dose (unit) Correctional Dose (unit) Correctional Dose (unit) Glargine (Lantus) - Ins Basal Dose (unit) NPH - Insulin Type Basal Dose (unit) 70/30 - Insulin Type	0113 Result 229 - Non-Carbohydrate B 0 2 2 (calculated) ydrate Based Patient	0820 198 ased Patient 2 2	1203 214 3 6	1743 165 3 3	2052 196 0 0 0 (calculated)	1411 210 3 6

**Figure 5.** Nursing insulin verification tool. (A) The nurses enter the patient's point of care testing result for blood glucose and use the patient's correctional scale to determine the proper correctional dose. The system then adds together the nutritional and correctional doses to come up with the total rapid-acting insulin dose. (B) This information populates a flowsheet.

Date:		04/12 0701	- 04/13 070	0		04	/13 0701 -	04/14 070	0		04/14	0701 - 04/	15 0700	
4 Hrs:	150	1 1901	2301	0301	0701	1101	1501	1901	2301	0301	0701	1101	1501	
▼ Glucose Results														
POCT BG Manual Entry		168 23	3 229		198	214	165	196						POCT
POCT BG Docked Result		168	229		198	214	165	196						POCT
Glucose, nonfasting	1 C				201									Glucos.
Aspart/Lispro/Reg Nutri		2	0 0		2	3	3	0						Aspart.
Aspart/Lispro/Reg Correct		2	2 2		2	6	3	0						Aspart.
Aspart/Lispro/Reg Total	, i i i i i i i i i i i i i i i i i i i	4	2 2		4	9	6	0						Aspart.
Glargine(Lantus)								7						Glargin.
2 RN Independent Check	E Whi	e R. Mak	. V. Dup		L, Lau	A.Mac	E, Whit	R. Burn						2 RN In.
▼ Glucose (mg/dl)														
Glucose,Serum	500		T 1								1			- 500
POCT BG(docked)	500 450 350 250 250 150 50													500 450 350 250 200 150 50
	350												-	+ 350
POCT ISTAT	250	_	-0-											- 250
	200							-•					-	- 200
	100	-												100
	50 +	-	+ +		-		-			+	-	+		+50
<ul> <li>Medication Dosing</li> </ul>			<i>n</i>		· · · · · ·					2		ç	· · · ·	
insulin aspart Peninsuln(Units)		4 2	2		4	9	6							insulin
insulin glargine Peninsuln(Units)								7						insulin
Dextrose based IVF											<i>w</i>	10		
dextrose Soln(mL)							250							dextro
▼ Labs										_				
Sodium, Serum / Plasma					135									Sodium.
Potassium, Serum / Plasma					4.6									Potassi
Chloride, Serum / Plasma					99									Chlorid.
Carbon Dioxide, Total					28									Carbon.
Magnesium, Serum / Plasma					1.8									Magne
Phosphorus, Serum / Plasma					3.2									Phosp
Creatinine					0.74									Creatin.
♥% of Meal Eaten														
Percent Meals Eaten (%)		5	0		70	75	75							Percen.

Figure 6. Insulin glucose flowsheet. In this view, 4-hour time intervals are chosen to allow a review of more data points. To view the exact times of blood glucose or insulin doses, a 1-hour time interval could instead be chosen.





Figure 7. Flowchart of steps to move from paper to computerized provider order entry hyperglycemia management order sets.

	rs - Order Details				?	Resize 🗘	Close X	Rx Sidebar 🔻			
🖌 Verify 😢	Reject 🔞 Reject & R/O	🗟 Interaction	ns 🕍 Edit I-W	ent 😤 Ne <u>w</u> I-Ve	nt 🔞 O <u>r</u> der Hx 🥥 Sh	ow Charge	More -	Medications, Inter	wentions, Snapshot		
Back to C	order List 🦛 4 of 5 🛋					Order ID: 1	59026041	tablet 1 ta	U) 150-150-200-300 mg		
	gular (NovoLIN R, H	HumuLIN F	R) 100 Unit	s in sodium	chloride 0.9 % 10			🖌 elvitegrav	r-cobicistat-	Daily With	
New					dered by: 5 Pharmacist				bine-tenofovir D) 150-150-200-300 mg	Breakfast	
Erom LICSE	IP ADULT CRITICAL CAR							tablet 1 ta			
	al Information	C INCOLINA IN	UDION			A Dela Dia			azole (NEXIUM) capsule	Daily	
	ai mormation					/ Edit Diss	pense in	20 mg entaNYL	IDUDACESICI 100	Every 48	
Order dose: Admin dose:	Not calculated	Route: Volume:	Intravenous	Frequency: For:	Continuous Until discontinued	Dispense	PHAR		(DURAGESIC) 100 atch 4 patch	Hours	
Autiliti UVSU.	Not calculated	Calc	Yes	Starting:	Today 2145	from:	SAT 1		de (LASIX) injection 20	Once	
		volume:		Ending:		First doses:	SAT 1	mg	1	Continuous	
		Stability:	24 Hours	Scheduled tim		Dispense	Conti		n dextrose 5 % 25,000 mL (100 units/mL)	Conenuous	
				3/10/2014	2145	code:	Motur	infusion			
						Dispense only once:	Yes		n dextrose 5 % 25,000 mL (50 units/mL)	Continuous	
Mmin instruct	ions: 🤌 Edit					Triggered	Yes	infusion			
Initial Insulin	Rate					511;			orphone in 0.9 % sodium (DILAUDID) 55 mg/55 mL	Continuous	
		20 m a 111 h 1		husian					) PCA infusion		
Blood glucos	se (BG) level must be >/= 1	20 mg/dL bef	ore starting inf	usion.					gular (NovoLIN R,	Continuous	
Starting infus									R) 100 Units in sodium 0.9 % 100 mL infusion		
	cose 120-150 mg/dL = 0.5 cose 151-200 mg/dL = 1 u							INV belati	acept (GCRC 39-42) 698	Once	
If current glu	cose 201-300 mg/dL = 1.5 cose > 300 mg/dL = 2 unit	units/hr						mg in soo mL IVPB	dium chloride 0.9 % 100		
il current glu	cose = 300 mg/dL = 2 unit	anli						V INV BIND	014 (CC# 13556) 100	Once	
Ongoing los	ulin Agorithm							mg in soo mL chem	dium chloride 0.9 % 250		
									umomab (AALL1121) 15	Continuous	
Section A If current BG	is < 60 then:								dium chloride 0.9 % 240		
1) STOP ins	ulin infusion								umomab (AALL1121) 15	Continuous	
<ol> <li>2) Give 50 m</li> <li>3) Notify prov</li> </ol>	iL D50 IV push vider							mcg in so	dium chloride 0.9 % 240		
4) Check BG	every 15 mins and repeat	treatment unt	I BG > 100 mg	/dL; then check	BG every 30 mins until B	3		mL infusi	on tumomab (AALL1121) 15	Casteria	
is >/= 120 m 5) When BG	ig/dL.		vious rate (0.3							Continuous	
	>/= 120 mg/dL, restart drig	o at 30% of ore			Round up to the neares				dium chloride 0.9 % 240		
tenth of a un	>/= 120 mg/dL, restart drip it.	o at 30% of pre	10000 1010 (0.0	s x previous rate)	Round up to the neares	t		mL infusi	on		
tenth of a un	it.	o at 30% of pre	1002 1810 (0.5	x previous rate)	Round up to the neares	t		mL infusi	on lumomab (AALL1121) 18	Continuous	
tenth of a un If current BG 1) STOP ins	it. i is 60-80 then: ulin infusion	o at 30% of pre	1003 1010 (0.5	x previous rate)	Round up to the neares	t		mL infusi	on lumomab (AALL1121) 18 odium chloride 0.9 % 240	Continuous	
tenth of a un If current BG 1) STOP ins 2) Give 25 m	it. is 60-80 then: ulin infusion nL D50 M push	o at 30% of pre	1000 1010 (0.5	, x previous raie)	Round up to the neares	t		ML infusi INV blinat mcg in so mL infusi INV blinat	on tumomab (AALL1121) 18 odium chloride 0.9 %240 on tumomab (AALL1121) 36		
tenth of a un If current BG 1) STOP insi 2) Give 25 m 3) Notify pro- 4) Check BG	it. i is 60-80 then: ulin infusion hL D50 M∕ push vider 9 every 15 mins and repeat							ML infusi INV blinat mcg in so mL infusi INV blinat	on tumomab (AALL1121) 18 odium chloride 0.9 %240 on tumomab (AALL1121) 36 odium chloride 0.9 %240		
tenth of a un If current BG 1) STOP insi 2) Give 25 m 3) Notify pro- 4) Check BG is >/= 120 m	it. i is 60-80 then: ulin infusion hL D50 M∕ push vider 9 every 15 mins and repeat	treatment unt	ii BG > 100 mg	g/dL; then check	BG every 30 mins until B	3		mL infusi INV blinat mcg in sc mL infusi INV blinat mcg in sc mL infusi INV blinat mcg in sc mL infusi	on tumomab (AALL1121) 18 vdium chloride 0.9 % 240 on tumomab (AALL1121) 36 vdium chloride 0.9 % 240 on Xoplatin (CC# 128510)		
tenth of a un If current BG 1) STOP insi 2) Give 25 m 3) Notify pro- 4) Check BG is >/= 120 m	iit. iis 60-80 then: ulin infusion hL D50 N/push vider 9 every 15 mins and repeat ig/dL. >/= 120 mg/dL, restart drip	treatment unt	ii BG > 100 mg	g/dL; then check	BG every 30 mins until B	3	7	mL infusi INV binat mcg in sc mL infusi INV binat mcg in sc mL infusi INV CARE 661 mg in	on umomab (AALL1121) 18 dium chloride 0.9 % 240 on umomab (AALL1121) 36 odium chloride 0.9 % 240 on lOplatin (CC# 128510) i dextrose 5% 341 mL	Continuous	
tenth of a un If current BG 1) STOP insi 2) Give 25 m 3) Notify pro- 4) Check BG is >/= 120 m 5) When BG	iit. iis 60-80 then: ulin infusion hL D50 N/push vider 9 every 15 mins and repeat ig/dL. >/= 120 mg/dL, restart drip	treatment unt	ii BG > 100 mg	g/dL; then check	BG every 30 mins until B	3	۲ ۲	mL infusi INV binat mcg in sc mL infusi INV binat mcg in sc mL infusi INV CARE 661 mg in	on tumomab (AALL1121) 18 vdium chloride 0.9 % 240 on tumomab (AALL1121) 36 vdium chloride 0.9 % 240 on Xoplatin (CC# 128510)	Continuous	
tenth of a un If current BG 1) STOP insi 2) Give 25 m 3) Notify pro- 4) Check BG is >/= 120 m 5) When BG tenth of a un	iit. iis 60-80 then: ulin infusion hL D50 N/push vider 9 every 15 mins and repeat ig/dL. >/= 120 mg/dL, restart drip	treatment unt	ii BG > 100 mg	p/dL; then check	BG every 30 mins until B	3	1 1	mL infusi INV binat mcg in sc mL infusi INV binat mcg in sc mL infusi INV CARE 661 mg in	on umomab (AALL1121) 18 dium chloride 0.9 % 240 on umomab (AALL1121) 36 odium chloride 0.9 % 240 on lOplatin (CC# 128510) i dextrose 5% 341 mL	Continuous Once	
tenth of a un If current BG 1) STOP insi 2) Give 25 m 3) Notify pro- 4) Check BG is >/= 120 m 5) When BG tenth of a un	iit. iis 60-80 then: ulin infusion Vder severy 15 mins and repeat g/dL. >/= 120 mg/dL, restart drig it.	treatment unt	ii BG > 100 mg	p/dL; then check	BG every 30 mins until B	3	2	mL infusi INV binat mcg in sc mL infusi INV binat mcg in sc mL infusi INV CARE 661 mg in	on umomab (AALL1121) 18 dium chloride 0.9 % 240 on umomab (AALL1121) 36 odium chloride 0.9 % 240 on lOplatin (CC# 128510) i dextrose 5% 341 mL	Continuous Once	Resi
tenth of a un If current BG 1) STOP insi 2) Give 25 m 3) Notify pro- 4) Check BG is >/= 120 m 5) When BG tenth of a un 4) MAR MAR	iit. iis 60-90 then: ulin infusion ii. D 50 N yush vder severy 15 mins and repeat gidL. ≫ = 120 mg/dL, restart drip iit.	treatment unt o at 40% of pre	II BG > 100 mg wious rate (0.4	p/dL; then check i i x previous rate)	BG every 30 mins until B Round up to the neares	3	1	mL infusi INV binat mcg in sc mL infusi INV binat mcg in sc mL infusi INV CARE 661 mg in	on umomab (AALL1121) 18 dium chloride 0.9 % 240 on umomab (AALL1121) 36 odium chloride 0.9 % 240 on lOplatin (CC# 128510) i dextrose 5% 341 mL	Continuous Once	
tenth of a un If current BG 1) STOP insi 2) Give 25 m 3) Notify pro- 4) Check BG is >/= 120 m 5) When BG tenth of a un 4) MAR MAR	iit. iis 60-80 then: ulin infusion Vder severy 15 mins and repeat g/dL. >/= 120 mg/dL, restart drig it.	treatment unt o at 40% of pre	II BG > 100 mg wious rate (0.4	p/dL; then check i i x previous rate)	BG every 30 mins until B Round up to the neares	3	¥ ۲	mL infusi INV binat mcg in sc mL infusi INV binat mcg in sc mL infusi INV CARE 661 mg in	on umomab (AALL1121) 18 dium chloride 0.9 % 240 on umomab (AALL1121) 36 odium chloride 0.9 % 240 on lOplatin (CC# 128510) i dextrose 5% 341 mL	Continuous Once	
tenth of a un If current BG 1) STOP ins: 2) Give 25 m 3) Notify pro- 4) Check BG is 2/a 120 m 5) When BG tenth of a un MAR	iit. iis 60-90 then: ulin infusion ii. D 50 N yush vder severy 15 mins and repeat gidL. ≫ = 120 mg/dL, restart drip iit.	treatment unt o at 40% of pre	li BG > 100 mg wious rate (0.4	pldL; then check i x previous rate) es Adult Insulin	BG every 30 mins until B Round up to the neares Roverity Ped Insulin R	3 t		mL infusi INV binat mcg in sc mL infusi INV binat mcg in sc mL infusi INV CARE 661 mg in	on umomab (AALL1121) 18 dium chloride 0.9 % 240 on umomab (AALL1121) 36 odium chloride 0.9 % 240 on lOplatin (CC# 128510) i dextrose 5% 341 mL	Continuous Once	
tenth of a un If current BG 1) STOP ins: 2) Give 25 m 3) Notify pro- 4) Check BG is >/= 120 m 5) When BG tenth of a un MAR Refresh 1 ALL Sche	iit. IIIs 60-80 then: Ulin Infusion L. D50 N/push vder severy 15 mins and repeat gdL. ≫ 120 mg/dL, restart drip it. ■ ■ ■ ■ ■ ■ Report MAR Note Rx Me	treatment unt o at 40% of pre	li BG > 100 mg wious rate (0.4	pldL; then check i x previous rate) es Adult Insulin	BG every 30 mins until B Round up to the neares Roverity Ped Insulin R	3 t		mL infusi INV binat mcg in sc mL infusi INV binat mcg in sc mL infusi INV CARE 661 mg in	on umomab (AALL1121) 18 dium chloride 0.9 % 240 on umomab (AALL1121) 36 odium chloride 0.9 % 240 on lOplatin (CC# 128510) i dextrose 5% 341 mL	Continuous Once	Resi
In the of a unit	III. III 60-00 then: Ulin Infusion L D50 Nyush vder severy 15 mins and repeat gdL. >>= 120 mg/dL, restart drip III. Report MAR Note Rx Me aduled PRN Continuous	treatment unt o at 40% of pre R, g issages Leg s Due/Overc	ii BG > 100 mg wious rate (0.4	pldL; then check i x previous rate) es Adult Insulin	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo	N Verify RxCommun		mL infusi INV binat mcg in sc mL infusi INV binat mcg in sc mL infusi INV CARE 661 mg in	on umomab (AALL1121) 18 dium chloride 0.9 %240 on dium chloride 0.9 %240 on Doplatin (CC# 128510) 1 dextrose 5% 341 mL Last Refresh: 2125	Continuous Once	Resi
tenth of a un If current BG 1) STOP ins: 2) Give 25 m 3) Notify pro- 4) Check BG is >/= 120 m 5) When BG tenth of a un MAR Refresh 1 ALL Sche	III. III 60-00 then: Ulin Infusion L D50 IV push vder sever 15 mins and repeat gdL. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>	treatment unt o at 40% of pre Px g sssages Leg 0 Due/Overo Qverdue	II BG > 100 mg vvious rate (0.4 lt [] lt [	pldL; then check i x previous rate) es Adult Insulin	BG every 30 mins until B Round up to the neares Roverity Ped Insulin R	N Verify RxCommun		mL infusi INV binat mcg in sc mL infusi INV binat mcg in sc mL infusi INV CARE 661 mg in	on umomab (AALL1121) 18 dium chloride 0.9 %240 on dium chloride 0.9 %240 on Doplatin (CC# 128510) 1 dextrose 5% 341 mL Last Refresh: 2125	Continuous Once	Resi
MAR MAR MAR MAR MAR MAR MAR MAR	III. IIII S0-80 then: Ulin Infusion L 500 V/push Vder severy 15 mins and repeat gdL. >>= 120 mg/dL, restart drip IIIIONAL and CORRECTION	theatment unt o at 40% of pre R <sub>x</sub> 2 Ssages Leg Stages Leg Qverdue 1300 NAL Doses (in	II BG > 100 mg vvious rate (0.4 12 [9] 14 14 14 14 14 14 14	p(dL; then check   x previous rate) es Aduit insulin e Pulls   Respin 100	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500	N Verify RxCommun rch 12, 2014 1600	nication	ML infusi W INV bina mc gin sc mL infusi W INV cARE 651 mg in Se Refresh	on tumomab (AALL1121) 18 dilum chloride 0.9 %240 on tumomab (AALL1121) 36 dilum chloride 0.9 %240 on Moplatin (CC# 128510) in dextrose 5% 341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR MAR MAR MAR MAR MAR MAR MAR	III. IIII 60-50 then: Ulin Infusion L D50 IV push wder gold >/= 120 mg/dL, restart drip III. Report MAR Note RX Me eduled PRN Continuous or Select Date:	theatment unt o at 40% of pre R <sub>x</sub> 2 Ssages Leg Stages Leg Qverdue 1300 NAL Doses (in	II BG > 100 mg vvious rate (0.4 12 [9] 14 14 14 14 14 14 14	p(dL; then check   x previous rate) es Aduit insulin e Pulls   Respin 100	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500	N Verify RxCommun rch 12, 2014 1600	nication	ML infusi W INV bina mc gin sc mL infusi W INV cARE 651 mg in Se Refresh	on tumomab (AALL1121) 18 dilum chloride 0.9 %240 on tumomab (AALL1121) 36 dilum chloride 0.9 %240 on Moplatin (CC# 128510) in dextrose 5% 341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR MAR MAR MAR MAR MAR MAR MAR	III. IIII S0-80 then: Ulin Infusion L 500 V/push Vder severy 15 mins and repeat gdL. >>= 120 mg/dL, restart drip IIIIONAL and CORRECTION	treatment unt o at 40% of pre o at 40% of pre Rs Sages Leg Due/Overc Qverdue 1300 NAL Doses (In dure/stops eat	II BG > 100 mg vvious rate (0.4 12 [9] 14 14 14 14 14 14 14	p(dL; then check   x previous rate) es Aduit insulin e Pulls   Respin 100	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500	N Verify RxCommun rch 12, 2014 1600	nication	ML infusi W INV bina mc gin sc mL infusi W INV cARE 651 mg in Se Refresh	on tumomab (AALL1121) 18 dilum chloride 0.9 %240 on tumomab (AALL1121) 36 dilum chloride 0.9 %240 on Moplatin (CC# 128510) in dextrose 5% 341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR MAR MAR MAR MAR MAR MAR MAR	III. IIII 560-50 then: Ulin Infusion L D50 IV push Wder severy 15 mins and repeat IgdL. >/= 120 mg/dL, restart drip IIII Report MAR Note Rx Me eduled PRN Continuous or Select Date:	treatment unt o at 40% of pre part 40% of pre Rx free Rx free Sssages Leg Sssages Leg Sssages Leg Sssages Leg Nucleover System University States (In dure/stops eat 0 mg/dL	II BG > 100 mg wious rate (0.4 la [9] la [9]	p/dL; then check if x previous rate) tes Adult insulin e Pulls Respination 100	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500 apart. Give correctional do	N Verify RxCommun rch 12, 2014 1600	nication	ML infusi W INV bina mc gin sc mL infusi W INV cARE 651 mg in Se Refresh	on tumomab (AALL1121) 18 dilum chloride 0.9 %240 on tumomab (AALL1121) 36 dilum chloride 0.9 %240 on Moplatin (CC# 128510) in dextrose 5% 341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR MAR MAR MAR MAR MAR MAR MAR	III. IIII 60-80 then: Ulin Infusion L D50 Nyush Wder Severy 15 mins and repeat IgdL. >/= 120 mg/dL, restart drig IIII Report MAR Note Rx Me eduled PRN Continuous or Select Date: 1200 RTIONAL and CORRECTION INTONAL AND CORRECTION IN	treatment unt o at 40% of pre R, g sssages Leg s Due/Overc Overdus 1500 NAL Doses (In dure/stops est 0 mg/dL total of the nut	II BG > 100 mg wous rate (0.4 ls [9] end Ling Ling Ling fue Overrid Julin ASPART) ing, HOLD nut rthonal PLUS c	p/dL; then check i x previous rate) tes Adult Insulin e Pulls Respin 100 ritional dose of A correctional dose	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500 spart. Give correctional do	N Verify RxCommun rch 12, 2014 1600 se of Aspart If B	iication	ML infusi W INV binat mcg in sc mL infusi M INV binat M INV binat mcg in sc mL infusi M INV binat M INV bi	on tumomab (AALL1121) 18 dilum chloride 0.9 %240 on umomab (AALL1121) 36 dilum chloride 0.9 %240 on Koplatin (CC# 128510) n dextrose 5%341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR MAR MAR MAR MAR MAR MAR Columnation MAR Columnation Charles MAR Columnation Charles MAR Columnation Charles	IIL UIII Infusion UIII Infusion UIIII Infusion UIIII Infusion Vider Severy 15 mins and repeat gdtL Vider Vid	treatment unt b at 40% of pre R, 2 SSSages Leg Due/Over Qverdue 1300 NAL Doses (in dure/stops eal 0 mg/dL total of the nut and CORREC	II BG > 100 mg wkous rate (0.4 wkous rate (0.4 kkous rate (0.4	VICL; then check in a previous rate)	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500 spart. Give correctional do	N Verify RxCommun rch 12, 2014 1600 se of Aspart If B	iication	ML infusi W INV binat mcg in sc mL infusi M INV binat M INV binat mcg in sc mL infusi M INV binat M INV bi	on tumomab (AALL1121) 18 dilum chloride 0.9 %240 on umomab (AALL1121) 36 dilum chloride 0.9 %240 on Koplatin (CC# 128510) n dextrose 5%341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR MAR MAR MAR MAR MAR MAR Columnation MAR Columnation Charles MAR Columnation Charles MAR Columnation Charles	III. III 60-00 then: Ulin Infusion L DS0 IV push wder severy 15 mins and repeat gdL. >/= 120 mg/dL, restart drip III. Report MAR Note Rx Me eduled PRN Continuous or Select Date: III. 1200 1200 101 G < 70 mg/dL or > 40 total dose given will be the	treatment unt b at 40% of pre R, 2 SSSages Leg Due/Over Qverdue 1300 NAL Doses (in dure/stops eal 0 mg/dL total of the nut and CORREC	II BG > 100 mg wkous rate (0.4 wkous rate (0.4 kkous rate (0.4	VICL; then check in a previous rate)	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500 spart. Give correctional do	N Verify RxCommun rch 12, 2014 1600 se of Aspart If B	iication	ML infusi W INV binat mcg in sc mL infusi M INV binat M INV binat mcg in sc mL infusi M INV binat M INV bi	on tumomab (AALL1121) 18 dilum chloride 0.9 %240 on umomab (AALL1121) 36 dilum chloride 0.9 %240 on Koplatin (CC# 128510) n dextrose 5%341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR	IIL UIII Infusion UIII Infusion UIIII Infusion UIIII Infusion Vider Severy 15 mins and repeat gdtL Vider Vid	Itreatment unt o at 40% of pre R, 2 ssages Leg Due/Over Qverdue 1300 NAL Doses (in NAL Doses (in dure/stops eat 0 mg/dL total of the nut and CORREC Silven 0-15 min	II BG > 100 mg wkous rate (0.4 kkous rate (0.4	p(dL; then check) (x previous rate) (x previous	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500 spart. Give correctional do	N Verify RxCommun rch 12, 2014 1600 se of Aspart If B	iication	ML infusi W INV binat mcg in sc mL infusi M INV binat M INV binat mcg in sc mL infusi M INV binat M INV bi	on tumomab (AALL1121) 18 dilum chloride 0.9 %240 on umomab (AALL1121) 36 dilum chloride 0.9 %240 on Koplatin (CC# 128510) n dextrose 5%341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR	III. III 60-50 then: Ulin Infusion L D50 IV push Wder Severy 15 mins and repeat gdL. 	Itreatment unt o at 40% of pre R, 2 ssages Leg Due/Over Qverdue 1300 NAL Doses (in NAL Doses (in dure/stops eat 0 mg/dL total of the nut and CORREC Silven 0-15 min	II BG > 100 mg wkous rate (0.4 kkous rate (0.4	p(dL; then check) (x previous rate) (x previous	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500 spart. Give correctional do	N Verify RxCommun rch 12, 2014 1600 se of Aspart If B	iication	ML infusi W INV binat mcg in sc mL infusi M INV binat M INV binat mcg in sc mL infusi M INV binat M INV bi	on tumomab (AALL1121) 18 dilum chloride 0.9 %240 on umomab (AALL1121) 36 dilum chloride 0.9 %240 on Koplatin (CC# 128510) n dextrose 5%341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR MAR MAR MAR MAR MAR MAR MAR	III. III. 60-00 then: Ulin Influsion L. DS0 IV push wder severy 15 mins and repeat gdL. 	Itreatment unt p at 40% of pre p at 40% of p at 40% of	II BG > 100 mg wous rate (0.4 wous rate (0.4 lend Ling Lin due Overrid ue Overrid sulin ASPART) sulin ASPART ing, HOLD nut ritional PLUS ( TTONAL doses is before meal) ydrate taken wi SN)	p(dL; then check i x previous rate) hes Adult Insulin e Pulls Respin fittonal dose of Ac correctional dose s below and be co ); th each meal.	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500 spart. Give correctional do	N Verify RxCommun rch 12, 2014 1600 se of Aspart If B	iication	ML infusi W INV binat mcg in sc mL infusi M INV binat M INV binat mcg in sc mL infusi M INV binat M INV bi	on tumomab (AALL1121) 18 dilum chloride 0.9 %240 on umomab (AALL1121) 36 dilum chloride 0.9 %240 on Koplatin (CC# 128510) n dextrose 5%341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR MAR MAR MAR MAR MAR MAR MAR	III. III S 60-90 then: Ulin infusion L D50 /V push Wder Severy 15 mins and repeat gdL. >/= 120 mg/dL, restart drip it. Report MAR Note Rx Me aduled PRN Continuous ) or Select Date: 1200 1100NAL and CORRECTION ent becomes NPO for proce ID If BG < 70 mg/dL or > 400 total dose given will be the k at both the NUTRITIONAL StTIONAL INSULIN DOSE (for me dose = 1 unit per 15 gr	Itreatment unt p at 40% of pre p at 40% of p at 40% of	II BG > 100 mg wous rate (0.4 wous rate (0.4 lend Ling Lin due Overrid ue Overrid sulin ASPART) sulin ASPART ing, HOLD nut ritional PLUS ( TTONAL doses is before meal) ydrate taken wi SN)	p(dL; then check i x previous rate) hes Adult Insulin e Pulls Respin fittonal dose of Ac correctional dose s below and be co ); th each meal.	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500 spart. Give correctional do	N Verify RxCommun rch 12, 2014 1600 se of Aspart If B	iication	ML infusi W INV binat mcg in sc mL infusi M INV binat M INV binat mcg in sc mL infusi M INV binat M INV bi	on tumomab (AALL1121) 18 dilum chloride 0.9 %240 on umomab (AALL1121) 36 dilum chloride 0.9 %240 on Koplatin (CC# 128510) n dextrose 5%341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR MAR MAR MAR MAR MAR MAR MAR	IIL IIII S 60-00 then: Ulin Infusion Li D50 N push Vder Severy 15 mins and repeat gdL // 120 mg/dL, restart drig it Report MAR Note Rx Me aduled PRN Continuous or Select Date: 1200 IIIIONAL and CORRECTIOI ent becomes NPO for proce ID If BG < 70 mg/dL or > 40 IIIIONAL INSULIN DOSE (f me dose = 1 unit per 15 gr RECTIONAL DOSE (For CU he CORRECTIONAL scale Glucose Range:	I treatment unt o at 40% of pre- ssages Leg s Due/Overc Overdue 1300 NAL Doses (in dure/stops eat 0 mg/dL total of the nut and CORREC Given 0-15 min ams of carboh ISTOM REGIME	II BG > 100 mg vious rate (0.4 vious rate (0.4 ling Ling Ling Ling Ling Ling Ling Ling L	p(dL; then check ( x previous rate) es Aduit insulin e Pulls Respin intional dose of Aduit protonal dose of Aduit correctional dose is below and be of bit the each meal.	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500 spart. Give correctional do s.	N Verify RxCommun tch 12, 2014 1600 See of Aspart If B	ication 3G > 130 mg	ML Infusi W INV binat mcg in sc mL infusi W INV binat mcg in sc mL infusi W INV CARE 661 mg in Sc Refresh 1700	on tumomab (AALL1121) 18 dumo chloride 0.9 %240 on tumomab (AALL1121) 36 dium chloride 0.9 %240 on Koplatin (CC# 128510) n dextrose 5% 341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR MAR MAR MAR MAR MAR MAR MAR	III. III 60-00 then: Ulin Infusion L DS0 IV push Wder Severy 15 mins and repeat gdL. III. Report MAR Note Rx Me eduled PRN Continuous I Or Select Date: III. IIII. IIII	I treatment unt o at 40% of pre- ssages Leg s Due/Overc Overdue 1300 NAL Doses (in dure/stops eat 0 mg/dL total of the nut and CORREC Given 0-15 min ams of carboh ISTOM REGIME	II BG > 100 mg vious rate (0.4 vious rate (0.4 ling Ling Ling Ling Ling Ling Ling Ling L	p(dL; then check ( x previous rate) es Aduit insulin e Pulls Respin intional dose of Aduit protonal dose of Aduit correctional dose is below and be of bit the each meal.	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500 spart. Give correctional do s.	N Verify RxCommun tch 12, 2014 1600 See of Aspart If B	ication 3G > 130 mg	ML Infusi W INV binat mcg in sc mL infusi W INV binat mcg in sc mL infusi W INV CARE 661 mg in Sc Refresh 1700	on tumomab (AALL1121) 18 dumo chloride 0.9 %240 on tumomab (AALL1121) 36 dium chloride 0.9 %240 on Koplatin (CC# 128510) n dextrose 5% 341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR MAR MAR MAR MAR MAR MAR MAR	IIL UIII Influsion L D50 then: UIII Influsion L D50 typush Wder Severy 15 mins and repeat gdL >/= 120 mg/dL, restart drig III Report MAR Note Rx Me aduled PRN Continuous or Select Date: D If BG < 70 mg/dL or > 40 Lotal dose given will be the k at both the NUTRITIONAL UNSULIN DOSE (or me dose = 1 unit per 15 gr RECTIONAL INSULIN DOSE (for CU he CORRECTIONAL Scale Glucose Range: omg/dL: 1 units less 50 mg/dL: 1 usits given	I treatment unt o at 40% of pre- sisages Leg sisages Leg sisages Leg sisages Leg Qverdue 1300 NAL Doses (in dure/stops eat 0 mg/dL total of the nut and CORREC Given 0-15 min ams of carboh ISTOM REGIME Delow to adjus mina per PRN (	II BG > 100 mg vious rate (0.4 vious rate (0.4 ling Ling Ling Ling Ling Ling Ling Ling L	p(dL; then check ( x previous rate) es Aduit insulin e Pulls Respin intional dose of Aduit protonal dose of Aduit correctional dose is below and be of bit the each meal.	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500 spart. Give correctional do s.	N Verify RxCommun tch 12, 2014 1600 See of Aspart If B	ication 3G > 130 mg	ML Infusi W INV binat mcg in sc mL infusi W INV binat mcg in sc mL infusi W INV CARE 661 mg in Sc Refresh 1700	on tumomab (AALL1121) 18 dumo chloride 0.9 %240 on tumomab (AALL1121) 36 dium chloride 0.9 %240 on Koplatin (CC# 128510) n dextrose 5% 341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR MAR MAR MAR MAR MAR MAR MAR	IIL UIII INTERPORTED TO THE PARTY OF THE PAR	I treatment unt o at 40% of pre- sisages Leg sisages Leg sisages Leg sisages Leg Qverdue 1300 NAL Doses (in dure/stops eat 0 mg/dL total of the nut and CORREC Given 0-15 min ams of carboh ISTOM REGIME Delow to adjus mina per PRN (	II BG > 100 mg vious rate (0.4 vious rate (0.4 ling Ling Ling Ling Ling Ling Ling Ling L	p(dL; then check ( x previous rate) es Aduit insulin e Pulls Respin intional dose of Aduit protonal dose of Aduit correctional dose is below and be of bit the each meal.	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500 spart. Give correctional do s.	N Verify RxCommun tch 12, 2014 1600 See of Aspart If B	ication 3G > 130 mg	ML Infusi W INV binat mcg in sc mL infusi W INV binat mcg in sc mL infusi W INV CARE 661 mg in Sc Refresh 1700	on tumomab (AALL1121) 18 dumo chloride 0.9 %240 on tumomab (AALL1121) 36 dium chloride 0.9 %240 on Koplatin (CC# 128510) n dextrose 5% 341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR  MAR  MAR  MAR  MAR  MAR  MAR  MAR	IIL IIS 60-80 then: Ulin infusion L D50 /V push Wder Severy 15 mins and repeat gdtL Vie 120 mg/dL, restart drig IIL III ONAL and CORRECTIOI Int becomes NPO for proce ID if BG < 70 mg/dL or 24 III ONAL and CORRECTIOI Int becomes NPO for proce ID if BG < 70 mg/dL or 24 III ONAL INSULIN DOSE (for CU he CORRECTIONAL Scale IGUICOSE Range: mg/dL: Treat for Hypoglyce 0 omg/dL: 1 units less 50 mg/dL: 1 units less 50 m	I treatment unt o at 40% of pre- sisages Leg sisages Leg sisages Leg sisages Leg Qverdue 1300 NAL Doses (in dure/stops eat 0 mg/dL total of the nut and CORREC Given 0-15 min ams of carboh ISTOM REGIME Delow to adjus mina per PRN (	II BG > 100 mg vious rate (0.4 vious rate (0.4 ling Ling Ling Ling Ling Ling Ling Ling L	p(dL; then check ( x previous rate) es Aduit insulin e Pulls Respin intional dose of Aduit protonal dose of Aduit correctional dose is below and be of bit the each meal.	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500 spart. Give correctional do s.	N Verify RxCommun tch 12, 2014 1600 See of Aspart If B	ication 3G > 130 mg	ML Infusi W INV binat mcg in sc mL infusi W INV binat mcg in sc mL infusi W INV CARE 661 mg in Sc Refresh 1700	on tumomab (AALL1121) 18 dumo chloride 0.9 %240 on tumomab (AALL1121) 36 dium chloride 0.9 %240 on Koplatin (CC# 128510) n dextrose 5% 341 mL Last Refresh: 2125	Continuous Once (?	Resi
MAR MAR MAR MAR MAR MAR MAR MAR	IIL UIIII Influsion UIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	I treatment unt o at 40% of pre- sisages Leg s Due/Overc Qverdue 1300 NAL Doses (in dure/stops eat 0 mg/dL total of the nut and CORREC Given 0-15 min ams of carboh ISTOM REGIME Delow to adjus mina per PRN (	II BG > 100 mg vious rate (0.4 vious rate (0.4 ling Ling Ling Ling Ling Ling Ling Ling L	p(dL; then check ( x previous rate) es Aduit insulin e Pulls Respin intional dose of Aduit protonal dose of Aduit correctional dose is below and be of bit the each meal.	BG every 30 mins until B Round up to the neares RN Verify Ped Insulin R atory Insulin Chemo Wednesday Ma 1500 spart. Give correctional do s.	N Verify RxCommun tch 12, 2014 1600 See of Aspart If B	ication 3G > 130 mg	ML Infusi W INV binat mcg in sc mL infusi W INV binat mcg in sc mL infusi W INV CARE 661 mg in Sc Refresh 1700	on tumomab (AALL1121) 18 dumo chloride 0.9 %240 on tumomab (AALL1121) 36 dium chloride 0.9 %240 on Koplatin (CC# 128510) n dextrose 5% 341 mL Last Refresh: 2125	Continuous Once (?	Resi

**Figure 8.** Pharmacist and nurse medication administration record (MAR) view of insulin orders. The insulin administration instructions were altered to allow formatting of the instructions to be clearly legible and well laid out for the pharmacist (A) and for the nurses in the MAR (B).



**Figure 9.** Utilization of glycemic management order set. Some of our order sets have not been frequently used, such as the subcutaneous insulin postmeal order set. Note that our inpatient computerized provider order entry go-live was June 2012, so these data points represent 1 month after go-live, 1 year later, and the current state.

glucometrics before and after this EHR implementation, an analysis that is currently ongoing.

Looking toward the future, there are several looming challenges. As hospitals become more patient centric, one change is the dietary services unit's move to patient-centered, hotel-style (Meals on Demand) room service. While this is laudable as an act of customer service, it introduces great challenges for glycemia management. For example, the system would have a hard time accounting for the scenario in which a blood glucose (BG) check is performed and intended before the meal but the patient then decides to eat 2 hours later. We currently have hospital floors piloting a system to try to ensure that skipping a meal does not mean skipping a BG check and correctional doses. Patients should also be involved in these workflows and be educated on their responsibility to work with hospital staff to optimize BG control on a flexible eating schedule. We are not aware of an available electronic system that provides integrated information to nursing and food service departments, identifying patients needing BG checks and premeal insulin prior to the delivery of the food tray.

Finally, inpatient insulin orders in CPOE should be thought of as part of the continuum of care rather than a separate entity. Electronic health records have allowed for patients' records to fluidly follow them from the ambulatory setting to the emergency department to the hospital and back to the ambulatory setting. Ideally, workflows and EHR build should be designed to take advantage of this, allowing glycemic-related orders to flow from setting to setting rather than viewing them each as mutually exclusive settings of care.

#### Abbreviations

BG, blood glucose; CHO, carbohydrate; CPOE, computerized provider order entry; DKA, diabetic ketoacidosis; EHR, electronic health record; ICU, intensive care unit; IV, intravenous; MAR, medication administration record; NPO, nil per os; SQ, subcutaneous.

#### Acknowledgments

Kethen So, PharmD, was instrumental in designing and building our glycemic management order sets. Russ Cucina, MD and Andy Auerbach, MD also provided guidance and input.

#### **Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

#### Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: R.R. has conducted speaking engagements supported by Novo and Merck within the past 5 years.

#### References

- American College of Endocrinology/American Diabetes Association Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control. *Diabetes Care*. 2006:1955-1962.
- Cook CB, Elias B, Kongable GL, Potter DJ, Shepherd KM, McMahon D. Diabetes and hyperglycemia quality improvement efforts in hospitals in the United States: current status, practice variation, and barriers to implementation. *Endocr Pract.* 2010;16(2):219-230.

- Centers for Medicare and Medicaid Services. Medicare and Medicaid programs: electronic health record incentive program. Final rule. *Fed Regist*. 2010;75(144):44313-44588.
- Blumenthal D, Tavenner M. The "meaningful use" regulation for electronic health records. *N Engl J Med*. 2010;363(6): 501-504.
- 5. Wei NJ, Wexler DJ. Basal-bolus insulin protocols enter the computer age. *Curr Diab Rep.* 2012;12(1):119-126.
- Wexler DJ, Shrader P, Burns SM, Cagliero E. Effectiveness of a computerized insulin order template in general medical inpatients with type 2 diabetes: a cluster randomized trial. *Diabetes Care*. 2010;33(10):2181-2183.
- Guerra YS, Das K, Antonopoulos P, et al. Computerized physician order entry- based hyperglycemia inpatient protocol and glycemic outcomes: the CPOE-HIP study. *Endocr Pract.* 2010;16(3):389-397.
- Maynard G, Wesorick DH, O'Malley C, Inzucchi SE; Society of Hospital Medicine Glycemic Control Task Force. Subcutaneous insulin order sets and protocols: effective design and implementation strategies. *J Hosp Med.* 2008;3(5 Suppl):29-41.

- Maynard G, Lee J, Phillips G, Fink E, Renvall M. Improved inpatient use of basal insulin, reduced hypoglycemia, and improved glycemic control: effect of structured subcutaneous insulin orders and an insulin management algorithm. *J Hosp Med.* 2009;4(1):3-15.
- Lee J, Clay B, Zelazny Z, Maynard G. Indication-based ordering: a new paradigm for glycemic control in hospitalized inpatients. *J Diabetes Sci Technol.* 2008;2(3):349-356.
- Pietras SM, Hanrahan P, Arnold LM, Sternthal E, McDonnell ME. State-of-the-art inpatient diabetes care: the evolution of an academic hospital. *Endocr Pract*. 2010;16(3):512-521.
- Neinstein A, Cucina R. An analysis of the usability of inpatient insulin ordering in three computerized provider order entry systems. *J Diabetes Sci Technol*. 2011;5(6):1427-1436.
- Schnipper JL, Liang CL, Ndumele CD, Pendergrass ML. Effects of a computerized order set on the inpatient management of hyperglycemia: a cluster-randomized controlled trial. *Endocr Pract.* 2010;16(2):209-218.
- Horsky J, Phansalkar S, Desai A, Bell D, Middleton B. Design of decision support interventions for medication prescribing. *Int J Med Inform.* 2013;82(6):492-503.